title: Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.
abstract: Both bisphosphonates and radiotherapy are highly effective for the management of bone metastases. Our in vitro study examined the cytotoxic effects resulting from combinations of ibandronate and ionising radiations (RX) in various sequences on breast cancer cells. Single radiation doses were given before, at halftime of, or after acute ibandronate incubation (48 h). Single or fractionated radiation doses were applied at the end of chronic ibandronate incubation (5 weeks). Combination of acute ibandronate exposure and single radiation doses led to synergistic cytotoxic effects in MDA-MB-231 cell line, but only with low ibandronate concentrations in MCF-7 cell line. In both cell lines, synergy was more marked when ibandronate followed RX. After long-term ibandronate exposure, only high single radiation doses induced synergistic effects in MDA-MB-231 cell line. Synergy was only detected with low ibandronate concentrations in MCF-7 cell line. In both cell lines, fractionated radiation doses exerted similar effects. The combination of ibandronate with radiation can exert synergistic effects on the inhibition of breast cancer cells growth, depending on cell line, drug sequence and dosage. Our data might provide a rationale for associating bisphosphonates and radiotherapy for the treatment of bone metastases from breast cancer.
authors.affiliation: Department of Internal Medicine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 1 Rue Héger-Bordet, 1000, Brussels, Belgium.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Journé
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
authors.forename: Carole
authors.initials: C
authors.lastname: Chaboteaux
authors.forename: Eric
authors.initials: E
authors.lastname: Kinnaert
authors.forename: Frieder
authors.initials: F
authors.lastname: Bauss
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Body
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D019583:Dose Fractionation, Radiation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D000077557:Ibandronic Acid; D011879:Radiotherapy Dosage; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid